Wulf O. Böcher

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Brian G. Feagan, William J. Sandborn, Geert D’Haens et al. · The Lancet · 2017 · 435 citations · Full text

Inflammation, Rheumatology, Placebo-controlled Phase 2 +8

Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide Analogues

Florian van Bömmel, Robert A. de Man, Heiner Wedemeyer et al. · Hepatology · 2009 · 330 citations

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

David W. Fitzsimons, Guido François, Andrew J. Hall et al. · Vaccine · 2005 · 179 citations

Vaccination, Booster Policy, Vaccine Development +9

Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen

Fareed Rahman, Anja Dahmen, Sabine Herzog‐Hauff et al. · Hepatology · 2000 · 156 citations

Humoral Immune Responses, Humoral Response, Immunology +18

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Brian G. Feagan, Julián Panés, Marc Ferrante et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 156 citations · Full text

Autoimmune Disease, Open-label Extension Study, Immunology +5